Phase II trial of pemetrexed (P) and gemcitabine (G) as first-line chemotherapy for elderly and/or poor performance status patients with stage IIIB/IV non-small cell lung cancer (NSCLC).

@article{Blakely2006PhaseIT,
  title={Phase II trial of pemetrexed (P) and gemcitabine (G) as first-line chemotherapy for elderly and/or poor performance status patients with stage IIIB/IV non-small cell lung cancer (NSCLC).},
  author={Johnetta Blakely and Frederick M. Schnell and Paul Kaywin and Mark R. Keaton and Barry V. Fortner and Amanda L Epperson and Lee S Schwartzberg},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 18_suppl},
  pages={17031}
}
17031 Background: Pemetrexed and gemcitabine have shown to be active agents in the treatment of locally advanced or metastatic NSCLC with favorable toxicity profiles. A recent phase I study examined a biweekly schedule of P and G in combination in order to establish a maximum tolerated dose in solid tumors. (Dudeck, A. ASCO 2004 Abstract 2141.) This established the dose for this study. METHODS After informed consent all patients received biweekly cycles of P 500 mg/m2 IV 10 minutes before G… CONTINUE READING